Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Davidson, BA, Ehrisman, J, Abbott, S, Harmon, Z, Secord, AA, Berchuck, A, Lee, PS, Valea, FA, Li, X, Havrilesky, LJ, and Hall, AHS. "Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer. (Accepted)" International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 37, no. 3 (May 2018): 252-255.

Full Text

Babic, A, Harris, HR, Vitonis, AF, Titus, LJ, Jordan, SJ, Webb, PM, Australian Ovarian Cancer Study Group, , Risch, HA, Rossing, MA, Doherty, JA, Wicklund, K, Goodman, MT, Modugno, F, Moysich, KB, Ness, RB, Kjaer, SK, Schildkraut, J, Berchuck, A, Pearce, CL, Wu, AH, Cramer, DW, and Terry, KL. "Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium." International journal of cancer 142, no. 3 (February 2018): 460-469.

Full Text

Liu, G, Mukherjee, B, Lee, S, Lee, AW, Wu, AH, Bandera, EV, Jensen, A, Rossing, MA, Moysich, KB, Chang-Claude, J, Doherty, JA, Gentry-Maharaj, A, Kiemeney, L, Gayther, SA, Modugno, F, Massuger, L, Goode, EL, Fridley, BL, Terry, KL, Cramer, DW, Ramus, SJ, Anton-Culver, H, Ziogas, A, Tyrer, JP, Schildkraut, JM, Kjaer, SK, Webb, PM, Ness, RB, Menon, U, Berchuck, A, Pharoah, PD, Risch, H, Pearce, CL, and Ovarian Cancer Association Consortium, . "Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence." American journal of epidemiology 187, no. 2 (February 2018): 366-377.

Full Text

Berchuck, A, Secord, AA, Moss, HA, and Havrilesky, LJ. "Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 36 (December 2017): 3999-4002.

Full Text

Moore, KN, Tritchler, D, Kaufman, KM, Lankes, H, Quinn, MCJ, Ovarian Cancer Association Consortium, , Van Le, L, Berchuck, A, Backes, FJ, Tewari, KS, Lee, RB, Kesterson, JP, Wenham, RM, Armstrong, DK, Krivak, TC, Bookman, MA, and Birrer, MJ. "Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study." Gynecologic oncology 147, no. 2 (November 2017): 396-401.

Full Text

Bateman, NW, Dubil, EA, Wang, G, Hood, BL, Oliver, JM, Litzi, TA, Gist, GD, Mitchell, DA, Blanton, B, Phippen, NT, Tian, C, Zahn, CM, Cohn, DE, Havrilesky, LJ, Berchuck, A, Shriver, CD, Darcy, KM, Hamilton, CA, Conrads, TP, and Maxwell, GL. "Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients." Cancer 123, no. 20 (October 2017): 4004-4012.

Full Text

Glubb, DM, Johnatty, SE, Quinn, MCJ, O'Mara, TA, Tyrer, JP, Gao, B, Fasching, PA, Beckmann, MW, Lambrechts, D, Vergote, I, Velez Edwards, DR, Beeghly-Fadiel, A, Benitez, J, Garcia, MJ, Goodman, MT, Thompson, PJ, Dörk, T, Dürst, M, Modungo, F, Moysich, K, Heitz, F, du Bois, A, Pfisterer, J, Hillemanns, P, AGO Study Group, , Karlan, BY, Lester, J, Goode, EL, Cunningham, JM, Winham, SJ, Larson, MC, McCauley, BM, Kjær, SK, Jensen, A, Schildkraut, JM, Berchuck, A, Cramer, DW, Terry, KL, and Salvesen, HB et al. "Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci." Oncotarget 8, no. 39 (September 2017): 64670-64684.

Full Text

Janouskova, H, El Tekle, G, Bellini, E, Udeshi, ND, Rinaldi, A, Ulbricht, A, Bernasocchi, T, Civenni, G, Losa, M, Svinkina, T, Bielski, CM, Kryukov, GV, Cascione, L, Napoli, S, Enchev, RI, Mutch, DG, Carney, ME, Berchuck, A, Winterhoff, BJN, Broaddus, RR, Schraml, P, Moch, H, Bertoni, F, Catapano, CV, Peter, M, Carr, SA, Garraway, LA, Wild, PJ, and Theurillat, J-PP. "Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors." Nature medicine 23, no. 9 (September 2017): 1046-1054.

Full Text

Skates, SJ, Greene, MH, Buys, SS, Mai, PL, Brown, P, Piedmonte, M, Rodriguez, G, Schorge, JO, Sherman, M, Daly, MB, Rutherford, T, Brewster, WR, O'Malley, DM, Partridge, E, Boggess, J, Drescher, CW, Isaacs, C, Berchuck, A, Domchek, S, Davidson, SA, Edwards, R, Elg, SA, Wakeley, K, Phillips, K-A, Armstrong, D, Horowitz, I, Fabian, CJ, Walker, J, Sluss, PM, Welch, W, Minasian, L, Horick, NK, Kasten, CH, Nayfield, S, Alberts, D, Finkelstein, DM, and Lu, KH. "Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials." Clinical cancer research : an official journal of the American Association for Cancer Research 23, no. 14 (July 2017): 3628-3637.

Full Text

"RE: “RISK PREDICTION FOR EPITHELIAL OVARIAN CANCER IN 11 UNITED STATES–BASED CASE-CONTROL STUDIES: INCORPORATION OF EPIDEMIOLOGIC RISK FACTORS AND 17 CONFIRMED GENETIC LOCI”." American Journal of Epidemiology 186, no. 1 (July 1, 2017): 130-130.

Full Text

Pages